← Back to Search

Unknown

MT-2990 for Dysmenorrhea

Phase 2
Waitlist Available
Research Sponsored by Mitsubishi Tanabe Pharma America Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years

Summary

This trial is testing a new medication called MT-2990 to see if it can help women who have moderate to severe pain from endometriosis. The women in the study have been diagnosed with endometriosis through surgery. The goal is to find out if MT-2990 is safe and effective in reducing their pain.

Eligible Conditions
  • Dysmenorrhea

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Side effects data

From 2021 Phase 2 trial • 76 Patients • NCT03840993
11%
Urinary tract infection
8%
Blood creatine phosphokinase increased
5%
Headache
5%
Corona virus infection
5%
Vulvovaginal mycotic infection
5%
Ageusia
5%
Anosmia
5%
Abdominal pain upper
5%
Fatigue
5%
Infusion site pain
5%
Pain
5%
Back pain
3%
Localised infection
3%
Axillary pain
3%
Cough
3%
Coronavirus test positive
3%
Breast tenderness
3%
Gastrointestinal disorder
3%
Rhinorrhoea
3%
Dysfunctional uterine bleeding
3%
Vulvovaginal pain
3%
Constipation
3%
Vomiting
3%
Upper respiratory tract infection
3%
Chest pain
3%
Conjunctivitis
3%
Migraine
3%
Nipple pain
3%
Pain in extremity
3%
Fibrocystic breast disease
3%
Pharyngitis streptococcal
3%
Nausea
3%
Nasopharyngitis
3%
Urine analysis abnormal
3%
Decreased appetite
3%
Dysgeusia
3%
Meralgia paraesthetica
3%
Breast cyst
3%
Abortion induced
3%
Vertigo
3%
Abdominal distension
3%
Injection site haemorrhage
3%
Pyrexia
3%
Hypercholesterolaemia
3%
Arthralgia
3%
Mood swings
3%
Nightmare
3%
Restlessness
3%
Acne
3%
Flushing
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
MT-2990

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: MT-2990Experimental Treatment1 Intervention
MT-2990, over 16 weeks
Group II: PlaceboPlacebo Group1 Intervention
Placebo, over 16 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MT-2990
2019
Completed Phase 2
~200

Find a Location

Who is running the clinical trial?

Mitsubishi Tanabe Pharma America Inc.Lead Sponsor
26 Previous Clinical Trials
3,226 Total Patients Enrolled
Mitsubishi Tanabe Pharma Development America, Inc.Lead Sponsor
21 Previous Clinical Trials
2,556 Total Patients Enrolled
Head of Clinical Development,Study DirectorMitsubishi Tanabe Pharma America Inc.
7 Previous Clinical Trials
747 Total Patients Enrolled
~11 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top